15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering Cogent Biosciences Inc, 7 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $16.00 to $67.00 (about 4.2x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $48.78 sits 43% above the current $34.18. The rating mix has stayed broadly stable, with Buy-side ratings easing from 9 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.58 next quarter toward $-1.11 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Moderate Buy
Strong Buy00%
Buy770%
Hold330%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to Cogent Biosciences Inc.
As of Sep, 7 of 10 firms rate COGT a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
COGT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.58
Range $-0.73 – $-0.49 · 8 analysts · +3% YoY
Next period, 8 analysts expect Cogent Biosciences Inc to earn $-0.58 a share (range $-0.73 – $-0.49), versus $-0.56 a year earlier. Full-year consensus is $-2.21, growing to $-1.11 the year after.
REVENUE · NEXT QUARTER
$6.0M
Range $0 – $13.8M · 8 analysts
Revenue is expected to reach $6.0M (range $0 – $13.8M). Full-year consensus is $6.0M, rising to $292.8M next year.
Top analysts covering Cogent Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on COGT.
#1
Michael Schmidt
Guggenheim · Rank #2
Buy
$52.00+52.1% to target
Overall win rate
55%
+ Follow
#2
David Nierengarten
Wedbush · Rank #66
Buy
$55.00+60.9% to target
Overall win rate
42%
+ Follow
#3
Ami Fadia
Needham · Rank #67
Hold
No targeton COGT
Overall win rate
47%
+ Follow
#4
Anupam Rama
JP Morgan · Rank #75
Buy
No targeton COGT
Overall win rate
51%
+ Follow
#5
Joel Beatty
Baird · Rank #80
Hold
$9.00-73.7% to target
Overall win rate
48%
+ Follow
COGT stock forecast FAQ
What is COGT's average 12-month price target?+
The 9 analysts with a live target average $48.78 for Cogent Biosciences Inc over the next 12 months, ranging from a $67.00 high to a $16.00 low.
Is COGT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 10 analyst ratings, 7 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for COGT?+
The Street-high target is $67.00 (JP Morgan), and the Street-low is $16.00 (Stifel). The average of all 9 active targets is $48.78.
How many Wall Street analysts cover COGT?+
10 analysts have an active rating on Cogent Biosciences Inc, and 9 firms carry a live 12-month price target.
Who is the most accurate analyst covering COGT?+
Among analysts who currently cover COGT, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #2). Their current call is Buy with a $52.00 target.
What is Cogent Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.58 per share (range $-0.73 – $-0.49) across 8 analysts. Full-year EPS is projected at $-2.21, rising to $-1.11 the following year.
How much revenue is Cogent Biosciences Inc expected to report next quarter?+
Consensus revenue is $6.0M (range $0 – $13.8M). Full-year revenue is projected at $6.0M, growing to $292.8M next year.
Have analysts been upgrading or downgrading COGT lately?+
As of Sep, 7 of 10 firms rate COGT a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their COGT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
